Review Article
Off-Label Uses of Anti-TNF Therapy in Three Frequent Disorders: Behçet’s Disease, Sarcoidosis, and Noninfectious Uveitis
Table 1
Characteristics of the different anti-TNF agents.
| | Infliximab | Etanercept | Adalimumab | Certolizumab pegol | Golimumab |
| Type | Monoclonal antibody against TNF- | TNF soluble receptor | Monoclonal antibody against TNF- | Monoclonal antibody against TNF- | Monoclonal antibody against TNF- |
| Composition | Chimeric antibody | Recombinant fusion protein | Recombinant monoclonal antibody | Monoclonal antibody | Monoclonal antibody |
| Origin | Human and murine | Human | Human | Human | Human |
| Mechanism of action | Binding to soluble and cell-bound TNF- | Binding to soluble TNF- and TNF- | Binding to soluble and cell-bound TNF- | Binding to soluble and cell-bound TNF- | Binding to soluble and cell-bound TNF- |
| Dose | 3–5 mg/kg at weeks 0, 2, and 6; then, every 4–8 weeks | 25–50 mg once or twice a week | 40 mg every other week | 400 mg every other week (maintenance every 4 weeks can be considered) | 50 mg once monthly |
| Administration route | Intravenous | Subcutaneous | Subcutaneous | Subcutaneous | Subcutaneous |
|
|